By Elric Langton | 6 September 2022
I have a financial interest in Poolbeg Pharma and Open Orphan.
Poolbeg Pharma (AIM: POLB, OTCQB: POLBF), a clinical-stage infectious disease pharmaceutical company with a unique capital light clinical model, announces its unaudited interim results for the six months to 30 June 2022.
It seems pretty clear the Company is mβ¦